过去一年中添加的文章，按日期排序

L'étude clinique du mois. Nouvelles études cliniques avec le sémaglutide injectable dans différentes populations à risque

A Scheen, P Delanaye, P Lancellotti - Revue Médicale de Liège, 2024 - orbi.uliege.be
2 天前 - … not only the good safety but also already the cardiovascular (CV) efficacy of semaglutide
in … trial), subjects with obesity and heart failure with preserved ejection fraction, with or …
相关文章

Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review

AA El-Solh, E Gould, K Aibangbee… - Expert Opinion on …, 2024 - Taylor & Francis
4 天前 - … , semaglutide, and tirzepatide in managing obese patients … in the semaglutide
treatment in people (STEP) with obesity … with BMI≥30 kg/m 2 free of diabetes (or BMI≥27 kg/m 2 …
相关文章 所有 2 个版本

The promise and hope of GLP-1 receptor agonists

P Sumithran, J Ard - The Lancet Diabetes & Endocrinology, 2024 - thelancet.com
11 天前 - … found that 2·4 mg semaglutide per week reduced MACE by … cardiovascular disease
and overweight or obesity but … ) 4 and the SELECT cardiovascular outcome trial, 2 which …
相关文章 所有 2 个版本
[PDF] oup.com

GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity

D Abasheva, A Ortiz… - Clinical Kidney …, 2024 - academic.oup.com
15 天前 - … persons with overweight or obesity, with or without T2DM, … pressure and kidney
and cardiovascular outcomes, as part … semaglutide 2.4 mg/week in overweight/obesity without …
相关文章 所有 4 个版本

Semaglutide and kidney function: direct kidney protection or an artifact?

I Ayoub, G Wong, RJ Glassock - Kidney International, 2024 - kidney-international.org
19 天前 - … the enrolled participants were obese (mean body … outcome was the total eGFR
slope. At a median follow-up of 3.4 years, the primary outcome significantly favored semaglutide …
相关文章 所有 2 个版本

Novel antidiabetic therapies in patients with peripheral artery disease: current perspective

M Janić, V Maggio, A Janež, M Rizzo - Frontiers in Clinical Diabetes and … - frontiersin.org
22 天前 - … cardiovascular outcome trials, but there was also no … obesity without diabetes,
since the SELECT trial showed a 20% reduction in MACE for people treated with semaglutide 2,4 …
相关文章

Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists

SS Khan, CE Ndumele, DS Kazi - JAMA, 2024 - jamanetwork.com
23 天前 - … diabetes, chronic kidney disease due to diabetes, and preexisting CVD with overweight
or obesity and without … parameters after stopping semaglutide or tirzepatide. Following …
相关文章 所有 2 个版本

Re-evaluating the safety profile of Semaglutide: An updated meta-analysis

F Rivera, GF MANGUBAT, J Magalong, MF Ansay… - Circulation, 2024 - ahajournals.org
25 天前 - … : Semaglutide is increasingly used in the management of type 2 diabetes mellitus
and obesity. … This meta-analysis evaluates the safety profile of semaglutide across patient …
相关文章

Eligibility and Preventable CVD Events in US Adults with Cardiovascular Disease and Overweight or Obesity: Projections from the SELECT Trial

H YAN, H Karthikeyan, W FAN, Q Yang, N Wong - Circulation, 2024 - ahajournals.org
25 天前 - … semaglutide and placebo primary composite CVD … diabetes and pre-diabetes,
respectively. The Figure shows the estimated number of primary and secondary CVD outcomes …
相关文章

Semaglutide and cardiovascular outcomes by blood pressure in the SELECT trial

S Verma, J Deanfield, Y Arbel, B Cariou, ALSA Matos… - Circulation, 2024 - ahajournals.org
25 天前 - … Conclusions: HT is highly prevalent in people with overweight or obesity and
atherosclerotic CV disease without diabetes and is associated with increased MACE. Semaglutide …
相关文章